Figma IPO, $SN Investment Case, $CDTX Insider Bet, $ORCL Cloud Deal, and More
Welcome back to the BBAE Blog, your trusted source for the latest investment insights and analyses from the BBAE team. This week, we’re excited to share some highlights that will keep you informed and ahead of the market. Don’t forget, some of our most valuable insights are available exclusively in the BBAE Pro app—download it now to unlock full access!
- Figma IPO S-1 Filing: Key Highlights
- Voss Capital: SharkNinja ($SN) Investment Case
- RA Capital Makes $100M Bet on Cidara After Breakthrough Flu Drug Results
- Trending Tickers: $ORCL Cloud Deal, $JACK Poison Pill, $DDOG S&P Boost
Need a reminder of why BBAE? We have one goal: to provide you with exclusive content and data to help you make informed investing decisions. Explore a wealth of market insights and potential investing opportunities that you can’t find anywhere else.
Figma IPO S-1 Filing: Key Highlights
Design software company Figma has filed for an IPO, aiming to list on the NYSE under the ticker $FIG in what could be one of 2025’s biggest public offerings. Best known for its collaborative, browser-based design tools like Figma Design and FigJam, the company operates on a freemium SaaS model and has seen strong growth fueled by product-led adoption and viral expansion within teams. Its S-1 filing reveals $749 million in 2024 revenue and profitability in early 2025, supported by high gross margins and rising enterprise traction. With over 11,000 customers generating more than $10K in ARR and plans to expand internationally and integrate AI, Figma is positioning itself as a key player in the global design and collaboration software market. Read the full article here.
Voss Capital: SharkNinja ($SN) Investment Case
Voss Capital presents SharkNinja as a compelling investment opportunity, positioning the consumer appliance innovator as a category-creating powerhouse trading at an attractive discount due to temporary tariff concerns. The firm significantly upsized their position during market volatility, highlighting SN’s exceptional track record of generating viral consumer phenomena (like the Ninja Swirl selling one unit every eight seconds at launch), strong financial performance with 20%+ revenue CAGR over 15 years, and substantial international growth runway with France and Germany alone potentially driving 8-9% company-wide revenue growth over the next five years. With 90% of US production moving outside China by Q2 2025, demonstrated pricing power, heavy R&D investment (7.2% vs. 3.5% peer average), and 25 new product launches planned for 2025, Voss sees SN as a rare combination of innovation leadership and execution excellence with a base case price target of $151 representing 65% upside potential. Read the full article here.
RA Capital Makes $100M Bet on Cidara After Breakthrough Flu Drug Results
Boston-based biotech investment firm RA Capital purchased 2,272,727 shares of Cidara Therapeutics ($CDTX) at $44.00 per share, totaling $100 million. The move increased RA Capital’s vested holdings in the company by 208%, marking their second-largest purchase out of 110 trades tracked by InsiderEdge. Cidara, a San Diego-based biotech company developing long-acting antivirals and immunotherapies, recently announced positive Phase 2b results for its non-vaccine flu prevention drug, CD388, which showed up to 76% protection from symptomatic influenza with a single dose and no major safety concerns. Notably, the insider transaction occurred after the trial results were made public—despite the stock already more than doubling in price.. You can track insider activity like this daily with InsiderEdge, available in the BBAE app.
Trending Tickers: $ORCL Cloud Deal, $JACK Poison Pill, $DDOG S&P Boost
This week, several companies made headlines with major announcements. Here’s a breakdown:
- Oracle ($ORCL): Oracle disclosed a cloud services agreement expected to generate over $30 billion in annual revenue starting in FY28. Though the buyer wasn’t named in the filing, reports linked the deal to OpenAI. The agreement marks a strong start to Oracle’s fiscal 2026 and reinforces its long-term cloud strategy.
- Jack in the Box ($JACK): The company adopted a shareholder rights plan (poison pill) after Biglari Capital revealed a near-10% stake. The move is aimed at protecting shareholder interests amid potential takeover activity and supporting its ongoing strategic shift to an asset-light model.
- Datadog ($DDOG): Datadog will be added to the S&P 500 index on July 9, 2025, following Juniper Networks’ removal. The inclusion boosts its visibility and is expected to increase passive fund inflows, signaling Datadog’s growing scale and financial strength in enterprise software and observability.
Read the full Weekly Highlights article here.
This article is for informational purposes only and is neither investment advice nor a solicitation to buy or sell securities. All investment involves inherent risks, including the total loss of principal, and past performance is not a guarantee of future results. Always conduct thorough research or consult with a financial expert before making any investment decisions. BBAE has no position in any investment mentioned.
